Jollife’s appointment to Glasgow-headquartered Novosound is a part of the tech firm’s launch of a new leadership team, led by CEO and co-founder Dave Hughes, and composed of Simon Patterson as Chief Commercial Officer, Gwen Grant as Chief Administrative Officer, and Jolliffe as CFO.

Jolliffe, who began his career in Grant Thornton LLP’s corporate finance team, was also previously Finance Director of UK Power Operations at Scottish Power, Chief Executive of Pyroguard — a subsidiary of CGI International — and was most recently CFO at Optoscribe.

Optoscribe — a Scots tech company that developed 3D lasers for the telecoms sector — was acquired by semiconductor manufacturer Intel Corporation in 2022.

On Jolliffe’s appointment, Hughes said: “It’s a remarkable coup to have David, a seasoned executive with a wealth of international experience from thriving technology companies and global industrial giants, join our team.

“As we embark on the next phase of growth and secure contracts across the UK, Europe, and North America, having David on board in Scotland, the birthplace of ultrasound, is invaluable.”

The company seeks to expand into North American markets with its wireless, wearable ultrasound technology, citing demand from clients in the healthcare, wellbeing, and fitness monitoring sectors.

“Recently, groundbreaking advancements in ultrasound technology have emerged, such as the recent work by the University of California San Diego into ultrasound system-on-patch (USoP) tech and the Internet of Medical Things (IoMT),” said Hughes.

“In this revolution towards accessible, wearable, healthcare devices, Novosound stands at the forefront, demonstrating that its commercially available technology is an integral part of this narrative.”

Recommended

• Levelling Up Your Business With Data Science
• Gartner: Global Government IT Spending to Grow Around 8% in 2023
• UK Hosts Military AI and Autonomy Trial

Last December, Novosound signed a commercial partnership agreement with PAVmed Inc., the Nasdaq-listed diversified medical technology company, to develop tech to advance intravascular imaging.

The PAVmed agreement furthers Novosound’s move into healthcare and its regional expansion into North America. Previous contract wins have included BAE Systems and GE Aviation, and Israeli-based digital health company dSound.

In 2022, Novosound secured its latest investment, a £3.7 million round led by Par Equity, supported by Foresight Group, Kelvin Capital, and Scottish Enterprise.